Resmed Announces Home Sleep Apnea Test Available Across the US

SAN DIEGO, California—Resmed, a health technology company focused on sleep, breathing and care delivered in the home, announced its home sleep apnea test, NightOwl, is now available across the United States. NightOwl is an FDA-cleared home sleep apnea test (HSAT) designed to offer health care providers a simplified, accurate and efficient way to diagnose obstructive sleep apnea (OSA) from the comfort of an individual’s home.

OSA, a sleep disorder where breathing repeatedly stops during sleep due to blocked upper airways, affects nearly one billion people globally, yet approximately 80% of cases remain undiagnosed and untreated. Additionally, a recent study published in The Lancet Respiratory Medicine found that treating OSA with CPAP therapy can significantly reduce the risk of death—underscoring the importance of accessible and simplified diagnostic options. NightOwl makes it easy to detect OSA with a small sensor worn on the fingertip and simple, easy-to-use digital platforms for both individuals and providers. By making OSA testing more convenient and accessible, NightOwl supports Resmed’s vision to help people achieve their full potential through better sleep and breathing, with care delivered in their own home.

“Now more than ever, people want health care experiences that are easy, convenient and accessible; however, navigating sleep apnea testing can be complex,” said Carlos M. Nunez, chief medical officer at Resmed. “With NightOwl, people can easily complete a sleep apnea test from the comfort of home using just a fingertip sensor and a smartphone. It also simplifies the process for providers. This is a meaningful step forward in Resmed’s mission to deliver life-changing health technology that people love.”  

NightOwl is a disposable HSAT device that records up to 10 nights of sleep data for a single patient, capturing night-to-night variability and providing clinicians with a comprehensive view of an individual’s sleep patterns. Sleep data is sent remotely to a cloud-based diagnostic platform for physician analysis and review, enabling quick interpretation, streamlining diagnostic workflows and helping individuals receive more timely diagnoses, if applicable. Additional key features of NightOwl, include:

• Auto-Scored Results: Raw patient data is autoscored with an algorithm that is clinically validated against polysomnography (PSG), saving time for sleep specialists and clinicians.
• Seamless Integration with Resmed’s Somnoware: Enhances diagnostic workflows by integrating with leading sleep lab management software, purchased separately.
• Fully Disposable: Eliminates the need for device returns, cleaning or reprocessing, reducing operational burdens for health care providers.
• Pairing with Resmed’s myAir App: The device pairs with the myAir app, providing individuals with step-by-step guidance throughout the testing process.

NightOwl uses peripheral arterial tonometry technology, a noninvasive method that measures blood flow changes, oxygen saturation and pulse rate changes, to detect OSA. According to a multicenter validation study, NightOwl results using peripheral arterial tonometry technology showed close agreement with expert-scored sleep lab testing PSG in its estimate of sleep apnea severity and clinical performance. This publication serves as additional clinical validation of the diagnostic accuracy of NightOwl, for both 3% and 4% hypopnea desaturation scoring rules, in addition to the studies indicating a high degree of accuracy that were reviewed by the FDA.

NightOwl is now widely available across the United States. Individuals interested in NightOwl should speak with their healthcare provider for more information. To learn more, visit: resmed.com/en-us/health-professionals/products/home-sleep-testing/nightowl.